Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.
Overview
Choosing between established healthcare giants often comes down to balancing income needs against growth potential. Both Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) offer massive scale but follow different strategic paths.
Bristol Myers Squibb focuses heavily on specialized biopharmaceuticals like oncology and cardiovascular care, while Johnson & Johnson operates a broader model spanning medicine and medical devices. Investors frequently compare them because they both provide essential medical solutions and consistent dividends, making them staples for those seeking stability.
Details
Bristol Myers Squibb operates as a pure-play biopharmaceutical company focusing on serious diseases. The company develops and sells medicines in the healthcare stocks sector across oncology, hematology, and immunology. It distributes these products primarily through wholesalers and specialty pharmacies, utilizing specific risk-management programs for drugs like Revlimid.
Source
Originally published at www.fool.com.
Related Articles
- A new bill would cap Medicare enrollees’ annual expenses at $5,000 — and could cost the government ‘tens of billions’
- Trump says Iran violated ceasefire with drone attacks on Strait of Hormuz ships
- Insurers shifted roof replacement costs onto homeowners thanks to a new federal rule — just in time for hail and hurricane season